Université de Bordeaux
FHU SMART Small Artery Disease transdisciplinary project
Cluster of excellence

Dr. David-Alexandre Tregouët

Dr. David-Alexandre Tregouët

Dr. David-Alexandre Tregouët is Reseach Director first class at Bordeaux Population Research Inserm Center U1219. His research program is focused on the application of machine learning and artificial intelligence based methods for cardiovascular precision medicine.

 

Summary CV

David-Alexandre Tregouët, PhD, born in 1973, started his research career with the development of statistical methods to analyze family data as well as genetic polymorphisms in the context of candidate association studies. He then turned to the development and the application of statistical tools for the analysis of high-throughput microarray data as part of genome-wide association and expression projects. He is partner with the GENMED (Laboratory of Excellence on Medical Genomics) to coordinate several genomics projects relying on whole exome/genome sequencing and high-throughput DNA arrays.
In parallel to these statistical and bioinformatics developments, he is participating in the design and the analysis of several epidemiological studies aiming at identifying susceptibility genes for cardiovascular diseases, more particularly venous thromboembolism (VTE) and pulmonary arterial hypertension. He is joint coordinator of the French EOVT, FARIVE, MARTHA, MARFAST and PILGRIM studies aimed at identifying genetic factors for VTE. Within the F-CRIN supported INNVOTE network that assembled all French clinician working in the field of VTE, he is responsible of the research programs on VTE genomics. Dr David-Alexandre Tregouët is an active convener of the International Network of Venous Thrombosis (INVENT) consortium and participate in international collaborative efforts on cardiovascular diseases including CHARGE, Cardiogenics, Cardomics, CADgenomics and MORGAM. More recently, his interests have turned to epigenetics as novel mechanisms contributing to the inter-individual susceptibility to human diseases with strong emphasis on the latest approaches on DNA methylation, microRNA and proteomic profiling towards the identification of novel molecular biomarkers for thrombosis.


From 2014 to 2018, he headed the department of "Genomics and Pathophysiology of Cardiovascular Diseases" within the INSERM UMR_S 1166 at the ICAN Institute for Cardiometabolism and Nutrition, on the Pitié-Salpêtrière Campus (Paris). His team was composed of clinicians, molecular and cellular biologists, epidemiologists, statistical geneticists and bioinformaticians. The team's aims were to : – identify novel genes and novel genetic variations associated with the susceptibility to cardiovascular diseases, both common or rare ; – to characterize their fonctional roles ; – to identify novel pathophysiological mechanisms with the ultimate goal to achieve a better clinical managment of patients. This research program was built on the application of high-throughput microarray and next-generation sequencing technologies in human collections and on experimental investigations on identified variants/genes. Main diseases of interest were cardiomyopathies, arrhythmias, arterial and venous thrombosis.

By the end of 2018, he joined the VINTAGE team " Bordeaux Population Research Center to focus his research program on the application of machine learning and artificial intelligence based methods for cardiovascular precision medicine.

Selected References

1. Yaniz-Galende E, Roux M, Nadaud S, Mougenot N, Bouvet M, Claude O, Lebreton G, Blanc C, Pinet F, Atassi F, Perret C, Dierick F, Dussaud S, Leprince P, Trégouët DA, Marazzi G, Sassoon D, Hulot JS. Fibrogenic Potential of PW1/Peg3 Expressing Cardiac Stem Cells. J Am Coll Cardiol. 2017;70(6):728-741. PMID:28774379 [Topic: RNA Seq data analysis in mouse cardiomyocytes]

2. Codoni V, Blum Y, Civelek M, Proust C, Franzén O; Cardiogenics Consortium; Leducq Consortium CADGenomics, Björkegren JL, Le Goff W, Cambien F, Lusis AJ, Trégouët DA. Preservation Analysis of Macrophage Gene Coexpression Between Human and Mouse Identifies PARK2 as a Genetically Controlled Master Regulator of Oxidative Phosphorylation in Humans. G3 (Bethesda). 2016 Oct 13;6(10):3361-3371. PMID: 27558669 [Topic: Integration Data analysis of human and mouse transcriptomic data]

3. Pulcrano-Nicolas AS, Proust C, Clarençon F, Jacquens A, Perret C, Roux M, Shotar E, Thibord F, Puybasset L, Garnier S, Degos V, Trégouët DA. Whole-Blood miRNA Sequencing Profiling for Vasospasm in Patients With Aneurysmal Subarachnoid Hemorrhage. Stroke. 2018;49(9):2220-2223. PMID: 30354977 [Topic: microRNA Seq data analyis in human samples]

4. Eyries M, Montani D, Girerd B, Perret C, Leroy A, Lonjou C, Chelghoum N, Coulet F, Bonnet D, Dorfmüller P, Fadel E, Sitbon O, Simonneau G, Tregouët DA, Humbert M, Soubrier F. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet. 2014;46:65-9. PMID: 24292273 [Topic: Whole Exome Sequencing Bioinformatics Analysis]

5. Germain M, Eyries M, Montani D, Poirier O, Girerd B, Dorfmüller P, Coulet F, Nadaud S, Maugenre S, Guignabert C, Carpentier W, Vonk-Noordegraaf A, Lévy M, Chaouat A, Lambert JC, Bertrand M, Dupuy AM, Letenneur L, Lathrop M, Amouyel P, de Ravel TJ, Delcroix M, Austin ED, Robbins IM, Hemnes AR, Loyd JE, Berman-Rosenzweig E, Barst RJ, Chung WK, Simonneau G, Trégouët DA, Humbert M, Soubrier F. Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension. Nat Genet. 2013 ;45:518-21. PMID: 23502781 [Topic: Genome Wide Association Bioinformatics Analysis]



TOP